Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells

European Urology

Volumn 68, Issue 6, 2015, Pages 939-945

  Onstenk, Wendy ^a   Sieuwerts, Anieta M ^a   Kraan, Jaco ^a   Van, Mai ^a   Nieuweboer, Annemieke J M ^a   Mathijssen, Ron H J ^a   Hamberg, Paul ^b   Meulenbeld, Hielke J ^c   De Laere, Bram ^d,e   Dirix, Luc Y ^d,e   Van Soest, Robert J ^a   Lolkema, Martijn P ^a   Martens, John W M ^a   Van Weerden, Wytske M ^a   Jenster, Guido W ^a   Foekens, John A ^a   De Wit, Ronald ^a   Sleijfer, Stefan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SINT FRANCISCUS GASTHUIS   (Netherlands)

^c GELRE HOSPITALS   (Netherlands)

^d GZA St Augustinus   (Belgium)

^e UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Androgen receptor; AR V7; Cabazitaxel; Castration resistant prostate cancer; CellSearch; Circulating tumor cells; Metastatic prostate cancer

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR SPLICE VARIANT 7; CABAZITAXEL; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN; TAXOID;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; CHEMISTRY; CLINICAL TRIAL; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR EMBOLISM;

AGED; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; TAXOIDS;

EID: 84983188883     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.07.007     Document Type: Article

References (26)

1. H.I. Scher, K. Fizazi, F. Saad, and et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
2. K. Fizazi, H.I. Scher, A. Molina, and et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
3. J.S. De Bono, S. Oudard, M. Ozguroglu, and et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
4. E. Basch, K. Autio, C.J. Ryan, and et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial Lancet Oncol 14 2013 1193 1199
5. C.J. Ryan, M.R. Smith, J.S. de Bono, and et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
6. T.M. Beer, A.J. Armstrong, D.E. Rathkopf, and et al. Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424 433
7. R. De Leeuw, L.D. Berman-Booty, M.J. Schiewer, and et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer Clin Cancer Res 21 2015 795 807
8. R.J. Van Soest, M.E. van Royen, E.S. de Morree, and et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer Eur J Cancer 49 2013 3821 3830
9. R. Nadal, Z. Zhang, H. Rahman, and et al. Clinical activity of enzalutamide in docetaxel-naive and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer Prostate 74 2014 1560 1568
10. S. Badrising, V. van der Noort, I.M. van Oort, and et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment Cancer 120 2014 968 975
11. D. Bianchini, D. Lorente, A. Rodriguez-Vida, and et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone Eur J Cancer 50 2014 78 84
12. M.T. Schweizer, X.C. Zhou, H. Wang, and et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer Eur Urol 66 2014 646 652
13. C.J. Pezaro, A.G. Omlin, A. Altavilla, and et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents Eur Urol 66 2014 459 465
14. R.J. Van Soest, E.S. de Morree, C.F. Kweldam, and et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer Eur Urol 67 2015 981 985
15. J.S. De Bono, H.I. Scher, R.B. Montgomery, and et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 2008 6302 6309
16. H.I. Scher, X. Jia, J.S. de Bono, and et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data Lancet Oncol 10 2009 233 239
17. D. Olmos, H.T. Arkenau, J.E. Ang, and et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience Ann Oncol 20 2009 27 33
18. M.H. Strijbos, J.W. Gratama, P.I. Schmitz, and et al. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel Eur J Cancer 46 2010 2027 2035
19. A. Goldkorn, B. Ely, D.I. Quinn, and et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer J Clin Oncol 32 2014 1136 1142
20. E.S. Antonarakis, C. Lu, H. Wang, and et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer N Engl J Med 371 2014 1028 1038
21. E.S. Antonarakis, C. Lu, B. Luber, and et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer JAMA Oncol 1 2015 582 591
22. H.I. Scher, S. Halabi, I. Tannock, and et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
23. H.I. Scher, G. Heller, A. Molina, and et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer J Clin Oncol 33 2015 1348 1355
24. W. Onstenk, J.W. Gratama, J.A. Foekens, and S. Sleijfer Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics Cancer Treat Rev 39 2013 691 700
25. A. Sieuwerts, J. Kraan, J. Bolt, and et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells J Natl Cancer Inst 101 2009 61 66
26. M. Yu, A. Bardia, B.S. Wittner, and et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition Science 339 2013 580 584